Swarm Oncology Unveils Highly Differentiated, Personalised T Cell Therapy Platform to Significantly Improve Treatment Outcome for Cancer Patients and Appoints Martin Olin as Chief Executive Officer

Company Overview - Swarm Oncology is a biotechnology company pioneering novel T cell therapies aimed at achieving long-term remission in patients with advanced solid cancers [1] - The company was co-founded by Professor John Campbell, a renowned T cell therapy manufacturing expert and immunologist, and Delin Ventures, a specialist life sciences investor [5][6] - Swarm Oncology has appointed Martin Olin as Chief Executive Officer, bringing over 25 years of executive leadership experience in the pharmaceutical and biotechnology industries [3][6] Technology and Platform - Swarm Oncology's breakthrough Swarm-T platform leverages immune system priming with proprietary ex vivo cell processing to generate unprecedented, large numbers of T cells with desired phenotypes [2] - The platform is designed to overcome key limitations of current immunotherapy approaches, including exhaustion, inadequate numbers, and lack of sufficient diversity [3] - The platform has demonstrated the ability to consistently produce highly potent T cells with optimal memory phenotypes, even in patients with compromised immune systems [3] Market Need and Impact - More than 82% of patients with advanced metastatic cancer die from their disease, highlighting a significant unmet need in solid cancers [2] - The company's T cell therapy platform delivers unprecedented numbers, specificity, potency, and durability of T cells, addressing critical limitations of current immunotherapies [3] - Swarm Oncology's approach has the potential to transform the treatment of solid cancers by generating a cellular immune response optimized to home to and infiltrate cancers, creating durable immune memory needed for long-term remissions [4] Leadership and Vision - Martin Olin, the newly appointed CEO, has a strong background in developing cancer therapies and has held key leadership roles at BerGenBio ASA, Symphogen A/S, SLS Invest, and Novo Nordisk [3][6] - Olin emphasized that existing therapies provide inadequate survival benefits, particularly in solid cancers, and expressed excitement about leading Swarm Oncology in advancing its mission of driving solid cancers into long-term remission [3] - Jonathan Hay, Partner at Delin Ventures, highlighted the potential of Swarm Oncology to transform cancer treatment and expressed support for Olin's appointment [4] Future Plans - Swarm Oncology expects to advance its first therapeutic candidate into clinical trials in the next 12-15 months [3][5] - The company is focused on developing novel potent T cell therapies to overcome major shortcomings of current immunotherapy approaches and drive solid cancers into long-term remission [5][6]